This document discusses the requirements for regulatory submissions for marketing authorization in various countries and regions.
It provides an overview of the key documents needed for marketing authorization in India, including application forms, manufacturing licenses, site documents, and product information.
It also summarizes the common ICH CTD format used for submissions to countries like the EU, US, and Japan, as well as the ASEAN CTD format used in Southeast Asian countries. The ASEAN CTD and ICH CTD formats are compared, highlighting similarities and differences in their organization.
Finally, specific documentation requirements are outlined for dossier submissions in countries like Myanmar, Vietnam, and Singapore, focusing on drug substance specifications, analytical methods, and
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
Regulatory requirnment and approval procedure of drugs in japan pptsandeep bansal
this ppt is about all the rules and regulations of drugs in Japan.this ppt contains the PMDA structure, DMF data, IND and NDA procedure, cosmetic regulations, post marketing survelliance etc.
The document filing for a pharmaceutical product is done in the form of dossier. The slides explain the format and content to be included in all the formats of dossiers.
plasma master file is a EU requirement for the apploval of the biologics or the biosimilars to the EU in a eCTD format or Nees as per the requirement type and should contain the above given details
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
this presentation describes briefly about Bioavailability and Bioequivalence requirements as per US FDA Code of Federal Regulations under title 21 and chapter 320
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
Understanding FDA Requirements Medical Devicesmarchell
The medical device market is experiencing explosive growth. Currently valued at $90 billion, market growth will continue to accelerate as demographics and market drivers increase their pressure for new and innovative product offerings.
Moreover, a substantial investment of time and resources is required to properly evaluate a new product idea and estimate its potential for success. So when a company executive declines a seemingly good product idea, what is probably being declined is the expense of properly evaluating the idea, and after having paid these expenses, the prospect of embarking on an expensive commercialization effort that has a 90 percent chance of failing.
The document filing for a pharmaceutical product is done in the form of dossier. The slides explain the format and content to be included in all the formats of dossiers.
plasma master file is a EU requirement for the apploval of the biologics or the biosimilars to the EU in a eCTD format or Nees as per the requirement type and should contain the above given details
21CFR 320- BIO AVAILABILITY AND BIO EQUIVALENCE REQUIREMENTSPallavi Christeen
this presentation describes briefly about Bioavailability and Bioequivalence requirements as per US FDA Code of Federal Regulations under title 21 and chapter 320
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
Understanding FDA Requirements Medical Devicesmarchell
The medical device market is experiencing explosive growth. Currently valued at $90 billion, market growth will continue to accelerate as demographics and market drivers increase their pressure for new and innovative product offerings.
Moreover, a substantial investment of time and resources is required to properly evaluate a new product idea and estimate its potential for success. So when a company executive declines a seemingly good product idea, what is probably being declined is the expense of properly evaluating the idea, and after having paid these expenses, the prospect of embarking on an expensive commercialization effort that has a 90 percent chance of failing.
TGA presentation: AusMedtech, 24 May 2017 TGA Australia
This presentation outlines reforms to the device regulatory system following the Expert Panel Review of Medicines and Medical Devices Regulation, reforms to the in vitro diagnostic devices (IVD) regulatory framework, reforms to the European and IVD system and the TGA's new Clinical Evidence Guidelines.
Dr. Abhijath's RA Document (CMC, Post Approvals, Regulation of Combination Pr...Abhijath Murali
Dear All,
Sharing the Information on Regulatory Affairs: CMC, Post Approvals, Regulation of Combination Products & Medical Devices.
Hope It would be helpful for you in your Future Journey.
All the Best!
With Regards,
Dr. Abhijath Murali
CTD is common technical document for submission of dossier and widely accepted format for ease of submission and evaluation purpose.
TRS 961, Annex 15, Guidelines on submission of documentation for a multisource (generic) finished product. General format: preparation of product dossiers in common technical document format
Objectives of CTD guidelines
To significantly reduce the time and resources needed to compile applications for registration of human pharmaceuticals
To facilitate regulatory reviews and communication with the applicant by a standard document of common elements
To simplify the exchange of regulatory information between Regulatory Authorities
common technical document vs electronic common technical document MayankGupta851
This presentation deals with brief overview of common technical document and its electronic version that is implemented by three ICH regions and common format for the dossier preparation for NDA application and documents required to prepare types of modules in database in specified format as specified by regulatory authorities.
Presented at length on 23 April and 21 May 2017 at ICCBS, HEJ and Getz Pharma Auditorium, Karachi in a Discussion Forum of about 800 practicing university qualified professionals of various pharmaceutical manufacturing industries
The dossier is a collection of documents that contain all the technical data of pharmaceutical products to be approved\ registered\ marketed in a country.
Pharma Knowledge Centre (PKC) “My Learning Life” is engaged to bridge
the real time knowledge gap between Academia and Industry to make
Students “Industry Ready” for Pharmaceutical, Biopharmaceutical and
Clinical Research organization.
Shamisha Learning Center, Ahmedabad, Gujarat, India-Specialized Training, Workshops and courses on Quality, Regulatory, R & D, Supply Chain and Manufacturing
2. Data in the dossier should enable us to answer
the following questions
What is the product?
Is the quality presented acceptable on grounds of safety and
efficacy?
Is the quality presented reproducible?
How long can the quality be maintained?
Quality must ensure consistency of safety and efficacy during the shelf life of all
batches produced
3. Requirements of Documents for Marketing Authorization in INDIA
1. Duly filled and signed form as per the requirement.
2. Copy of the challan of Fee paid.
3. Land possession document.
4. List of Directors
5. Memorandum of article of association
6. Authority letter for authorized signatury.
7. Copy of the form 46 (approval of CT)
8. Copy of the approved plant layout.
9. Site Master File
10. Copy of NOC of Pollution control board.
11. Water system P & I diagram.
12. HVAC details and Area qualification report.
13. Process flow chart
14. List of SOPs
15. Specification
16. Copy of approval and contract of Waste disposal.
4. Requirements of Documents for Marketing Authorization in INDIA
17. List of equipments for Manufacturing.
18. List of equipments for Quality Control.
19. List of Products in 6 copies.
20. Draft Label.
21. List of Technical Staff.
22. Any other document as required. e.g. Inspection report,
Compliance report, Check compliance report, CoAs, Undertaking
etc.
5. Commonly used forms as per D & C Act 1940
1. Form 24 Application for products of C, C (1) and X
2. Form 25 License C, C (1) and X
3. Form 27 Application for products excluding C, C (1) and X
4. Form 28 License for products excluding C, C (1) and X
5. Form 29 License for purpose of examination, test or analysis.
6. Form 30 Application for purpose of examination, test or analysis.
7. Form 35 Inspection book.
8. Form 46 Permission/approval for manufacture of New Drug
Formulation.
6. Track sheet for the documents required for filling and approvals.
1. Product-Brand
2. Product-Generic
3. Npd Form for the country
4. IDR Proof
5. DCI-Domestic
6. NOC-Export
7. Mfg. Lic.
8. COPP
9. BMR
10. BPR
11. RM Spec/STP
12. FP Spec/STP
13. PM Spec/STP
14. RM COA
15. FP COA
16. API COA
7. Track sheet for the documents required for filling and approvals.
17. AMV-FP
18. PVP/PVR
19. Stability Acc Study data
20. Stability Real Time Study data
21. BE/BA or CT Report
22. FP Samples
23. API Open Part DMF
24. FP Chromatogram
25. API Chromatogram
26. Working Standard
27. Literature
8. ICH / Non-ICH countries
International Conference of Harmonization (ICH)
• European Union
• USA
• Japan
The ICH countries developed a common format for submissions of
new marketing authorization applications (MAAs) CTD format
Non-ICH countries covers all countries outside ICH includes also
Canada, Switzerland, Australia and ASEAN
9. ASEAN: Association of South-East Asian Nations
Population: 500 millions
Member countries (10)
10. Common Wealth if Independent States (CIS countries)
Member countries (11+1)
1 Russia
2. Ukrain
3. Kazakhastan
4. Belarus (Head Quarter)
5. Uzbekistan
6. Turmenistan (associate member)
7. Azerbaijan
8. Georgia
9. Armenia
10. Kyrgyzstan
11. Tajakistan
12. Moldova
11. RoW (Rest of the World)
RoW is Rest of the World excluding
UK, USA, Other Euro American Countries (OEAC) including
Australia, New Zealand & Canada
12. General requirements for marketing authorization application for
Biosimilars –ICH-CTD
ICH-CTD Dossier
Complete ICH CTD dossier requested for ICH countries and some Non- ICH
countries (like Canada, Switzerland, Australia, Croatia)
Organization of ICH-CTD
ICH-CTD dossier (Module 1, 2, 3 4, and 5)
Module 1: Administrative documents Labeling texts and mock-ups
Module 2: Overviews and Summaries
Module 3: Quality Data
Module 4: Preclinical Data
Module 5: Clinical Data
13. ASEAN: Association of South-East Asian Nations/ non-ICH countries
A-CTD Dossier
For Market Authorization in ASEAN, Dossier is filed mainly in A-CTD format
Organization of A-CTD
A-CTD dossier (Part I, II, III and IV)
Part I : Administrative Information
Part II :Quality Document
Part III :Preclinical / Safety Document
Part IV : Clinical / Efficacy Document
14. ASEAN: Status of ACTD Implementation
For ASEAN countries the ASEAN CTD has become mandatory from 2009 onwards!
15. ASEAN: Association of South-East Asian Nations
Organization of A-CTD ASEAN-CTD and ICH-CTD
Main differences are the organization of data and the numbering of sections
16. Organization of A-CTD ASEAN-CTD and ICH-CTD
ASEAN-CTD ICH-CTD
Part II Module 2
Quality Summary Quality Overall Summary
& Module 3
Body of Data Quality
Quality Part contains all the data related to Drug Substance (DS) and Drug
Product (DP) with complete details but basic contents remains the same for
both
17. ICH-CTD Module 3
Module 3
3.1 MODULE 3 TABLE OF CONTENTS
3.2 BODY OF DATA
3.2.S DRUG SUBSTANCE
3.2.S.1 General Information
3.2.S.2 Manufacture Module 3 (Cont.)
3.2.S.3 Characterisation 3.2.A APPENDICES
3.2.S.4 Control of Drug Substance 3.2.A.1 Facilities and Equipment
3.2.S.5 Reference Standards or Materials 3.2.A.2 Adventitious Agents Safety Evaluation
3.2.S.6 Container Closure System 3.2.A.3 Novel Excipients
3.2.S.7 Stability 3.2.R REGIONAL INFORMATION
3.2.P DRUG PRODUCT 3.3 LITERATURE REFERENCES
3.2.P.1 Description and Composition of the Drug
Product
3.2.P.2 Pharmaceutical Development
3.2.P.3 Manufacture
3.2.P.4 Control of Excipients
3.2.P.5 Control of Drug Product
3.2.P.6 Reference Standards or Materials
3.2.P.7 Container Closure System
3.2.P.8 Stability
18. A-CTD Part II Section C (DRUG SUBSTANCE)
Section C: Body of Data S 5 Reference Standards or Materials
S DRUG SUBSTANCE S 6 Container Closure System
S 1 General Information S 7 Stability
S 1.1 Nomenclature Stability Summary and Conclusion
S 1.2 Structural formula Post-approval Stability Protocol and Stability
S 1.3 General Properties Commitment
S 2 Manufacture Stability Data
S 2.1 Manufacturer(s)
S 2.2 Description of Manufacturing Process and Process Controls
S 2.3 Control of Materials
S 2.4 Controls of Critical Steps and Intermediates
S 2.5 Process Validation and/or Evaluation
S 2.6 Manufacturing Process Development
S 3 Characterization
S 3.1 Elucidation of Structure and Characteristic
S 3.2 Impurities
S 4 Control of Drug Substance
S 4.1 Specification
S 4.2 Analytical Procedures
S 4.3 Validation of Analytical Procedures
S 4.4 Batch Analyses
S 4.5 Justification of Specification
19. A-CTD Part II Section C (DRUG PRODUCT)
P DRUG PRODUCT P 5 Control of Finished Product.
P 1 Description and Composition P 5.1 Specification
P 2 Pharmaceutical Development P 5.2 Analytical Procedures.
P 2.1 Information on Development Studies P 5.3 Validation of Analytical Procedures
P 2.2 Component of Drug Product P 5.4 Batch analyses
P 2.2.1 Active Ingredients P 5.5 Characterization of Impurities
P 2.2.2 Excipients P 5.6 Justification of Specification
P 2.3 Finished Product P 6 Reference Standards or Materials
P 2.3.1 Formulation Development P 7 Container closure system
P 2.3.2 Overages P 8 Product Stability.
P 2.3.3 Physicochemical and Biological Properties Stability Summary and Conclusion
P 2.4 Manufacturing Process Development Post-approval stability protocol and stability
P 2.5 Container Closure System commitment
P 2.6 Microbiological Attributes Stability Data
P 2.7 Compatibility P 9 Product Interchangeability
P 3 Manufacture
P 3.1 Batch Formula Section D: Key Literature References
P 3.2 Manufacturing Process and Process Control
P 3.3 Controls of Critical Steps and Intermediates
P 3.4 Process Validation and/or Evaluation
P 4 Control of Excipients
P 4.1 Specification
P 4.2 Analytical Procedures
P 4.3. Excipients of Human and Animal Origin
P 4.4 Novel Excipients
20. Data required for Dossier filing of Drug Substance (DS) in Myanmar/ Vietnam
• API specification as per EP
• STP of DS as per specification
For Dossier filing in Myanmar only Drug Substance Specification and Analytical
Procedures are required, Method Validation is not required
21. Additional documents required by the Regulatory agency for Dossier
Filing In Singapore (ASEAN)
Special documents requested:
Appendix 8: Singapore Quality Overall Summary for Biologic
Validation sheet
Singapore Stability sheet
Administrative documents, e.g.
CPP
GMP certificates
Letter of authorizations (Power of Attorneys)
Labeling documents
EU approval letters
EU Assessment Reports (from benchmarking countries)
TGA approval letters, if available
Patent declaration form
COAs of DS and DP
22. Additional documents required by the Regulatory agency for Dossier
Filing In Taiwan (ASEAN)
Plant Master File registration required before MAA can be submitted
Administrative documents, e.g.
CPP
GMP certificates
Letter of authorizations (Power of Attorneys)
Labeling documents
COAs of DS and DP
Batch Records requested for DP
Detailed information about quality part requested, even very
confidential information
23. Additional documents required by the Regulatory agency for Dossier
Filing In China (ASEAN)
Detailed information about quality part requested, even very confidential
information
Administrative documents, e.g.
Application Forms
CPP
GMP certificates
Letter of authorizations (Power of Attorneys)
Labeling documents
SOPs for test methods
COAs of DS and DP
Only one manufacturer can be registered for DS and DP
24. Important web sites
DCGI-CDSCO : http://www.cdsco.nic.in/
DCGI Guidelines : http://www.google.com/#hl=en&sclient=psy-
ab&q=dcgi+guidelines+pdf&oq=DCGI+&gs_l=hp.1.3.0l4.258.6177.6.9734.9.5.4.0.0.0.118.561.0j5.
5.0...0.0...1c.1.7.psy-
ab.3rAuntWOcwU&pbx=1&bav=on.2,or.r_qf.&bvm=bv.44442042,d.bmk&fp=670e618efc243f0d&b
iw=1280&bih=923
e.g.
cdsco.nic.in/CDSCO-GuidanceForIndustry.pdf
www.cdsco.nic.in/Guidance_for_New_Drug_Approval-23.07.2011
WHO : http://www.who.int/en/
ICH : www.ich.org/
US-FDA : www.fda.gov/
CHMP : www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/...jsp
MHRA : www.mhra.gov.uk/ (Medicines and Healthcare products Regulatory Agency)
EMA : www.ema.europa.eu/
TGA : www.tga.gov.au/ ( Therapeutic Goods Administration, Australia's)